Inactief instrument

Andere talen OYSR POIN

Aandelen

OYST

US69242L1061

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Viatris Completes Acquisitions of Oyster Point Pharma, Famy Life Sciences	03-01-23
OYSTER POINT PHARMA, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	03-01-23
Oyster Point Pharma, Inc. Announces Board Resignations	03-01-23
Oyster Point Pharma, Inc.(NasdaqGS:OYST) dropped from NASDAQ Composite Index	03-01-23
Oyster Point Pharma, Inc.(NasdaqGS:OYST) dropped from S&P TMI Index	03-01-23
Viatris Inc. completed the acquisition of Oyster Point Pharma, Inc. from a group of shareholders.	03-01-23
Oyster Point Pharma, Inc.(NasdaqGS:OYST) dropped from S&P Global BMI Index	02-01-23
Oyster Point Pharma, Inc.(NasdaqGS:OYST) dropped from NASDAQ Biotechnology Index	16-12-22
OYSTER POINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Oyster Point Pharma, Inc. - OYST	07-12-22
Oyster Point Pharma Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635	05-12-22
Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	02-12-22
Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	02-12-22
OYSTER POINT PHARMA, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	10-11-22
Earnings Flash (OYST) OYSTER POINT PHARMA Reports Q3 Revenue $5.6M	10-11-22
Oyster Point Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	10-11-22
Oyster Point Pharma Reports Third Quarter 2022 Financial Results and Recent Business Highlights	10-11-22
Oyster Point Pharma Reports Third Quarter 2022 Financial Results and Recent Business Highlights	10-11-22
North American Morning Briefing : Midterm Outcome -3-	09-11-22
OYSTER POINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Oyster Point Pharma, Inc. - OYST	09-11-22
OYSTER POINT PHARMA, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	08-11-22

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen OYSR POIN

Aandelen

OYST

US69242L1061

Andere talen

Filters